Jeremy R. Graff, the President and Chief Development Officer of Allarity Therapeutics, Inc., has reported several transactions involving common stock and restricted stock units in a recent filing with the SEC. This activity, disclosed on October 9, 2026, underscores Graff's ongoing engagement with the company and his management of equity holdings.
Graff's filing reveals multiple transactions dated January 22, 2026, and September 30, 2026. These transactions include the acquisition of shares through restricted stock units and the sale of common stock, reflecting a strategic approach to managing his investments in Allarity Therapeutics.
Background
Allarity Therapeutics, Inc., based in Boston, Massachusetts, operates within the pharmaceutical preparations sector. The company focuses on developing innovative cancer therapies. Graff has been actively involved with the company, as indicated by his recent SEC filings, which include multiple reports of stock transactions.
What the Filing Says
The SEC filing details Graff's transactions, including:
- Acquisition of 48,147 shares of common stock on January 22, 2026.
- Acquisition of 17,814 shares of common stock at a price of $1.18 per share on the same date.
- Acquisition of 39,494 shares of common stock on September 30, 2026, at a price of $0.97 per share.
Graff's total holdings post these transactions amount to 269,122 shares, including both common stock and restricted stock units.
Impact
This update may affect various stakeholders, including investors and analysts monitoring Allarity Therapeutics. Graff's actions could signal confidence in the company's direction and growth potential, which may influence investor sentiment. The pharmaceutical preparations sector, where Allarity operates, is highly competitive, and such disclosures are critical for maintaining transparency and trust with stakeholders.
What's Next
The filing does not say what happens next.